Disaggregated Revenues

6 Months Ended

Jun. 30, 2022

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
	(unaudited)				(unaudited)
Net product sales
Trokendi XR	$	71,602	$	78,777	$	134,434	$	150,596
Oxtellar XR	29,958		25,022		57,479		52,392
GOCOVRI	24,700		—		47,301		—
APOKYN	20,447		26,981		38,895		48,711
Qelbree	11,099		315		19,382		315
Other(1)	7,653		7,533		15,432		14,995
Total net product sales	$	165,459	$	138,628	$	312,923	$	267,009
Royalty revenues	4,592		2,701		9,634		5,252
Total revenues	$	170,051	$	141,329	$	322,557	$	272,261

______________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Trokendi XR accounted for 43% of the Company’s total net product sales for both the three and six months ended June 30, 2022, and approximately 57% and 56% of the Company's total net product sales for the three and six months ended June 30, 2021, respectively.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 25% of our total net product sales for both the six months ended June 30, 2022 and 2021, and collectively accounted for more than 80% and 85% of our total net product sales for the six months ended June 30, 2022 and 2021, respectively.

Royalty revenues include noncash royalty revenues. The Company recognized noncash royalty revenue of $2.5 million and $4.7 million, for the three and six months ended June 30, 2022, respectively. The Company recognized noncash royalty revenue of $2.2 million and $4.4 million, for the three and six months ended June 30, 2021, respectively. Refer to Note 16, Commitments and Contingencies.